---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-243413"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2024-10-25T23:59:59+00:00"
generated_at: "2026-05-30T10:04:51.755564+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# IDEAYA reports 33% ORR in Phase 1 IDE397 in MTAP-deletion urothelial cancer and NSCLC

## Summary
- Overall response rate 33% (1 CR, 8 PR) in 27 evaluable patients; all 9 responses confirmed.
- Confirmed ORR by tumor: 40% (4/10) urothelial, 38% (3/8) squamous NSCLC, 22% (2/9) adenocarcinoma NSCLC.
- Disease control rate 93%; median treatment duration >6.2 months; 15 of 27 patients still on treatment.
- ctDNA molecular response rate 81% (≥50% reduction) and 33% (≥90% reduction) in 21 reportable patients.
- Favorable safety: 18% Grade 3+ drug-related AEs; no drug-related SAEs or discontinuations; IDE397 + Trodelvy combo to start Q4 2024.

## SEC filing metadata
- accession: 0001193125-24-243413
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2024-10-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000119312524243413/0001193125-24-243413-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000119312524243413/d898951d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-243413
- JSON: https://secwatch.observer/filing/0001193125-24-243413.json
- Plain text: https://secwatch.observer/filing/0001193125-24-243413.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.